Loading
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Latest quote
$2.17
−$0.04 · -1.81%
After-hours
$2.1219
−$0.0481 · -2.22%
Oct 8, 5:03 PM ET
Regular session · ET · Market data may be delayed.
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Day range
Current $2.17
52-week range
Current $2.17
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
58
Mixed
Risk
54
Elevated Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Day range
Current $2.17
52-week range
Current $2.17
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.12M USD | 13.95M USD | 15.18M USD | 14.69M USD | 6.39M USD |
| Cost of goods sold | 8.11M USD | 7.12M USD | 13.73M USD | 14.3M USD | 6.77M USD |
| Gross profit | 8.01M USD | 6.83M USD | 1.45M USD | 384K USD | −374K USD |
| Research and development | 43.87M USD | 50.59M USD | 47.44M USD | 45.8M USD | 29.12M USD |
| Selling, general, and administrative | 42.58M USD | 56.57M USD | 58.95M USD | 52.63M USD | 42.2M USD |
| Operating expenses | 86M USD | 106.93M USD | 106.39M USD | 98.43M USD | 71.32M USD |
| Interest income | 11.52M USD | 16.67M USD | 17.76M USD | 4.6M USD | 326K USD |
| Interest expense | — | — | — | — | 22K USD |
| Depreciation and amortization | 6.1M USD | 6.18M USD | 5.58M USD | 3.94M USD | 2.56M USD |
| Operating income | −77.99M USD | −100.1M USD | −104.94M USD | −98.04M USD | −71.7M USD |
| Net income | −73.6M USD | −86.6M USD | −86.28M USD | −92.97M USD | −71.17M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.00
84.33% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.39M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF779.96K0.00%95.4B USD0.05%$233.13-0.15%
iShares Micro-Cap ETFIWC293.57K0.02%1.33B USD0.60%$182.79-0.31%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM140K0.12%116.75M USD0.73%$15.90-0.44%
Avantis U.S. Small Cap Equity ETFAVSC135.99K—3.04B USD0.25%$69.96+0.47%
U.S. Micro Cap Portfolio ETFDFMC83.6K0.00%7.52B USD0.43%$57.70+0.35%
Invesco RAFI US 1500 Small-Mid ETFPRFZ51.15K0.00%2.68B USD0.36%$52.82+0.17%
Dimensional - US Small Cap ETFDFAS34.45K0.00%33.66B USD0.31%$78.10+0.23%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Micro Cap Portfolio ETFDFMCInvesco RAFI US 1500 Small-Mid ETFPRFZDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
